CA3088998A1 - Quinolone analogs and their salts, compositions, and method for their use - Google Patents

Quinolone analogs and their salts, compositions, and method for their use Download PDF

Info

Publication number
CA3088998A1
CA3088998A1 CA3088998A CA3088998A CA3088998A1 CA 3088998 A1 CA3088998 A1 CA 3088998A1 CA 3088998 A CA3088998 A CA 3088998A CA 3088998 A CA3088998 A CA 3088998A CA 3088998 A1 CA3088998 A1 CA 3088998A1
Authority
CA
Canada
Prior art keywords
composition
compound
pharmaceutical composition
stored
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3088998A
Other languages
English (en)
French (fr)
Inventor
Hshiou-Ting Liu
John Soong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Senhwa Biosciences Inc
Original Assignee
Senhwa Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Senhwa Biosciences Inc filed Critical Senhwa Biosciences Inc
Publication of CA3088998A1 publication Critical patent/CA3088998A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CA3088998A 2018-02-15 2019-02-15 Quinolone analogs and their salts, compositions, and method for their use Pending CA3088998A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862631171P 2018-02-15 2018-02-15
US201862631174P 2018-02-15 2018-02-15
US62/631,171 2018-02-15
US62/631,174 2018-02-15
PCT/US2019/018225 WO2019168688A2 (en) 2018-02-15 2019-02-15 Quinolone analogs and their salts, compositions, and method for their use

Publications (1)

Publication Number Publication Date
CA3088998A1 true CA3088998A1 (en) 2019-09-06

Family

ID=67805108

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3088998A Pending CA3088998A1 (en) 2018-02-15 2019-02-15 Quinolone analogs and their salts, compositions, and method for their use

Country Status (11)

Country Link
US (2) US20190374550A1 (enExample)
EP (1) EP3752149A4 (enExample)
JP (1) JP7445597B2 (enExample)
KR (1) KR102914215B1 (enExample)
CN (1) CN112334133A (enExample)
AU (1) AU2019227294B2 (enExample)
CA (1) CA3088998A1 (enExample)
IL (1) IL276513A (enExample)
RU (1) RU2020130050A (enExample)
TW (1) TWI884912B (enExample)
WO (1) WO2019168688A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119185322A (zh) 2015-11-20 2024-12-27 生华生物科技股份有限公司 用于治疗癌症的四环喹诺酮类似物组合疗法
EP3752149A4 (en) 2018-02-15 2022-03-02 Senhwa Biosciences, Inc. QUINOLONE ANALOGUES AND THEIR SALTS, COMPOSITIONS AND METHODS OF USE
US20210046071A1 (en) * 2019-08-14 2021-02-18 Senhwa Biosciences, Inc. Tetracyclic compounds and their salts, compositions, and methods for their use
WO2021030686A1 (en) * 2019-08-14 2021-02-18 Senhwa Biosciences, Inc. Crystalline forms of quinoline analogs and salts thereof, compositions, and their methods for use
WO2022051491A1 (en) * 2020-09-02 2022-03-10 Senhwa Biosciences, Inc. Pharmaceutical compositions of tetracyclic quinolone analogs and their salts
WO2023059148A1 (ko) * 2021-10-08 2023-04-13 기초과학연구원 항암 치료 개선을 위한 2-클로로-n,n-디에틸에틸아민 염산염의 용도
CN118005653B (zh) * 2023-04-23 2024-12-10 信义核新(北京)生物科技有限公司 喹诺酮类似物及其用途

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
ATE269848T1 (de) 1999-04-07 2004-07-15 Univ Virginia Calciumkanalblocker als antikrebsmittel
AU2002361493A1 (en) 2001-12-13 2003-06-23 Wockhardt Limited New generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation, compositions and use as medicaments
US6900224B2 (en) 2002-07-31 2005-05-31 The Procter & Gamble Company Antimicrobial quinolones, their compositions and uses
PL1633724T3 (pl) 2003-03-12 2011-10-31 Kudos Pharm Ltd Pochodne ftalazynonu
MXPA06000993A (es) 2003-07-25 2006-08-31 Cancer Rec Tech Ltd Inhbidores triciclicos de parp.
US20050118291A1 (en) 2003-09-10 2005-06-02 Mian-Ying Wang Formulations and methods for treating breast cancer with Morinda citrifolia and methylsulfonymethane
WO2005033108A1 (en) 2003-09-22 2005-04-14 Janssen Pharmaceutica, N.V. 7-amino alkylidenyl-heterocyclic quinolones and naphthyridones
SG150548A1 (en) 2003-12-01 2009-03-30 Kudos Pharm Ltd Dna damage repair inhibitors for treatment of cancer
LT2612862T (lt) 2004-05-13 2017-01-25 Icos Corporation Chinazolinonai kaip žmogaus fosfatidilinozitol-3-kinazės delta inhibitoriai
NZ553746A (en) 2004-09-17 2010-06-25 Cylene Pharmaceuticals Inc Quinolone analogs as cell proliferation inhibitors
EP1928887B1 (en) 2005-08-05 2014-12-17 Senhwa Biosciences, Inc. Methods of preparing quinolone analogs
EP1926372A2 (en) 2005-08-19 2008-06-04 Cylene Pharmaceuticals, Inc. HUMAN RIBOSOMAL DNA(rDNA) AND RIBOSOMAL RNA (rRNA) NUCLEIC ACIDS AND USES THEREOF
AR057555A1 (es) 2005-10-27 2007-12-05 Merck Frosst Canada Ltd Un inhibidor de fosfodiesterasa-4 4-oxo-1-(3-sustituido fenil-1,4-dihidro-1,8-naftiridin-3-carboxamida y un procedimiento de preparacion del mismo
WO2007056113A2 (en) 2005-11-02 2007-05-18 Cylene Pharmaceuticals, Inc. Methods for targeting quadruplex sequences
US20100063046A1 (en) 2006-05-17 2010-03-11 Whitten Jeffrey P Tetracyclic imidazole analogs
WO2007146831A2 (en) 2006-06-08 2007-12-21 Cylene Pharmaceuticals, Inc. Quinolone analogs derivatized with sulfonic acid, sulfonate or sulfonamide
US20110112086A1 (en) 2006-06-08 2011-05-12 Cylene Pharmaceuticals, Inc. Pyridinone analogs
GB0701992D0 (en) 2007-02-02 2007-03-14 7Tm Pharma As Grehlin Receptor Modulators
WO2008131134A1 (en) 2007-04-17 2008-10-30 Cylene Pharmaceuticals, Inc. Hydrazide compounds and uses thereof
KR101601332B1 (ko) 2007-10-05 2016-03-08 센화 바이오사이언시즈 인코포레이티드 퀴놀론 유사체 및 이와 관련된 방법
AU2008201871A1 (en) 2008-04-16 2009-11-26 Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts Inhibition of angiogenesis and tumor metastasis
WO2012122645A1 (en) 2011-03-11 2012-09-20 Sarissa Inc. Methods of treating cancer by inhibition of dna repair proteins
WO2012123938A1 (en) 2011-03-17 2012-09-20 Tel Hashomer Medical Research Infrastructure And Services Ltd. Quinolone analogs for treating autoimmune diseases
WO2013133876A1 (en) 2011-12-07 2013-09-12 The Regents Of The University Of California Biomarkers for prediction of response to parp inhibition in breast cancer
US9044421B2 (en) 2012-03-28 2015-06-02 Genus Oncology, Llc Treating MUC1-expressing cancers with combination therapies
US9856320B2 (en) 2012-05-15 2018-01-02 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
WO2014209804A1 (en) 2013-06-24 2014-12-31 Biomed Valley Discoveries, Inc. Bispecific antibodies
EP3074391B1 (en) * 2013-11-28 2019-07-31 Tel Hashomer Medical Research Infrastructure And Services Ltd. Rna polymerase i inhibitors and uses thereof
PT3134123T (pt) 2014-02-21 2021-03-22 Nektar Therapeutics India Pvt Ltd Agonistas seletivos de il-2rbeta em combinação com um anticorpo anti-ctla-4 ou um anticorpo anti-pd-1
CN119185322A (zh) 2015-11-20 2024-12-27 生华生物科技股份有限公司 用于治疗癌症的四环喹诺酮类似物组合疗法
ES2959536T3 (es) * 2015-12-14 2024-02-26 Senhwa Biosciences Inc Formas cristalinas de análogos de quinolona y sus sales
US9957282B2 (en) * 2015-12-14 2018-05-01 Senhwa Biosciences, Inc. Crystalline forms of quinolone analogs and their salts
WO2017100925A1 (en) 2015-12-15 2017-06-22 British Columbia Cancer Agency Branch Metal complexed therapeutic agents and lipid-based nanoparticulate formulations thereof
WO2017205832A1 (en) * 2016-05-26 2017-11-30 Fred Hutchinson Cancer Research Center L-myc pathway targeting as a treatment for small cell lung cancer
EP3752149A4 (en) 2018-02-15 2022-03-02 Senhwa Biosciences, Inc. QUINOLONE ANALOGUES AND THEIR SALTS, COMPOSITIONS AND METHODS OF USE
WO2021030686A1 (en) 2019-08-14 2021-02-18 Senhwa Biosciences, Inc. Crystalline forms of quinoline analogs and salts thereof, compositions, and their methods for use
US20210046071A1 (en) 2019-08-14 2021-02-18 Senhwa Biosciences, Inc. Tetracyclic compounds and their salts, compositions, and methods for their use
WO2022051491A1 (en) 2020-09-02 2022-03-10 Senhwa Biosciences, Inc. Pharmaceutical compositions of tetracyclic quinolone analogs and their salts

Also Published As

Publication number Publication date
EP3752149A2 (en) 2020-12-23
TWI884912B (zh) 2025-06-01
JP2021513986A (ja) 2021-06-03
US11524012B1 (en) 2022-12-13
KR102914215B1 (ko) 2026-01-20
WO2019168688A3 (en) 2019-10-10
IL276513A (en) 2020-09-30
WO2019168688A2 (en) 2019-09-06
AU2019227294B2 (en) 2023-06-15
AU2019227294A1 (en) 2020-09-10
CN112334133A (zh) 2021-02-05
RU2020130050A (ru) 2022-03-15
US20190374550A1 (en) 2019-12-12
WO2019168688A9 (en) 2019-11-14
JP7445597B2 (ja) 2024-03-07
EP3752149A4 (en) 2022-03-02
KR20200131251A (ko) 2020-11-23
TW202000195A (zh) 2020-01-01

Similar Documents

Publication Publication Date Title
US11524012B1 (en) Quinolone analogs and their salts, compositions, and method for their use
JP6763919B2 (ja) Ｄｎａ−ｐｋ阻害剤としての（ｓ）−ｎ−メチル−８−（１−（（２’−メチル−［４，５’−ビピリミジン］−６−イル）アミノ）プロパン−２−イル）キノリン−４−カルボキサミドおよびその重水素化誘導体の共結晶
EP3890749B1 (en) Cdk9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
TW201534305A (zh) 使用組合療法治療癌症之方法
JP6147246B2 (ja) Ａｋｔ及びｍｅｋ阻害剤化合物の組み合わせ、及び使用方法
US20250282752A1 (en) Quinazoline Derivative Salt Crystal Form, Preparation Method and Application
AU2020328590B2 (en) Tetracyclic compounds and their salts, compositions, and methods for their use
ES3032458T3 (en) Crystalline form of the hydrochloride salt of 2-((1r,4r)-4-((3-(3-(trifluoromethyl)phenyl) imidazo[1,2-b]pyridazin-6-yl)amino)cyclohexyl)propan-2-ol
US20220062294A1 (en) Pharmaceutical compositions of tetracyclic quinolone analogs and their salts
US20210046082A1 (en) Crystalline forms of quinoline analogs and salts thereof, compositions, and their methods for use
US20140275234A1 (en) Compositions and methods of using crystalline forms of wortmannin analogs
HK40016954A (en) Combinations of akt and mek inhibitor compounds, and methods of use
HK40052182B (en) Hexahydroimidazopyridopyrimidinone, analogs and salts thereof and their use in therapy
HK1193754A (en) Combinations of akt and mek inhibitor compounds, and methods of use

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220926

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20240801

R00 Party data change recorded

Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R00-R119 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REVOCATION OF AGENT REQUEST

Effective date: 20241217

Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R00-R116 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPOINTMENT OF AGENT REQUEST

Effective date: 20241217

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241217

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241220

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241220

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241220

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241223

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250401

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250401

R17 Change to representative recorded

Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R17-R121 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REVOCATION OF AGENT REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250704

Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R17-R117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPOINTMENT OF AGENT REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250704

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250704

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250721

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20251121

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251210

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251210

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260112

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260112

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260112